Clinical Trial VICCNCPED10100
Title
An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Principal Investigator(s)
Details
- Protocol No. VICCNCPED10100
- Open Date: 02/22/2010
- Staging: Phase III
- Age Group: Children
- Scope: National
- Objective: The primary objective of this study is to evaluate the safety of romiplostim as a long-term treatment in pediatric thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura.
- Disease Sites: Pediatrics; Benign Hematologic
- Therapies: Therapy (NOS)
- Drugs: None Specified
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: 20090340
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
